Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.77B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 1.00M
Average 0.84M
Returns on capital
Maze Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-36.9%
avg -280.6%
ROIC
-37.7%
avg -65.2%
ROA
-33.0%
avg -57.1%
Analysis
ROA is currently the strongest return metric at -33.0% versus its period average of -57.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Jason V. Coloma | Chief Executive Officer & Director | USD 1.09M | 50 | 12.96K | 0.02% |
Harold S. Bernstein | President of Research & Development and Chief Medical Officer | USD 874.58K | 66 | — | — |
Courtney J. Phillips | General Counsel & Corporate Secretary | USD 354.78K | 51 | — | — |
Misbah Tahir | CFO & Principal Accounting Officer | USD 304.94K | 51 | 20.00K | 0.04% |
Andrew Good | VP & Corporate Controller | — | — | — | — |
Maarten Hoek | Chief Scientific Officer | — | — | — | — |
Vipin Vijayakumar | Senior Vice President of Technology and Business Operations | — | — | — | — |
Winston Tse | Senior Vice President of Drug Discovery | — | — | — | — |
Nazila Habibizad | Senior Vice President of Technical Operations & Supply Chain | — | 63 | — | — |
Susan Limb | Senior Vice President of Clinical Development | — | — | — | — |
Matt Krause | Senior Vice President of Human Resources | — | — | — | — |
Atul Dandekar | Chief Strategy & Business Officer | — | 54 | 0 | <0.01% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 2, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
92
$19.58M
Net Transaction Value
−$19.58M
Net selling
Most Active
Coloma Jason V
29 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 2, 26Nov 2, 2026 | Coloma Jason V Indirect | Sell | $68K$67,990.09 |
| Nov 2, 26Nov 2, 2026 | Coloma Jason V Indirect | Sell | $10.4K$10,385.39 |
| Nov 2, 26Nov 2, 2026 | Coloma Jason V Indirect | Sell | $166K$165,977.22 |
| Nov 2, 26Nov 2, 2026 | Coloma Jason V Indirect | Sell | $799.4K$799,413.49 |
| Oct 29, 26Oct 29, 2026 | Dandekar Atul Direct | Sell | $240.5K$240,531.75 |
| Oct 1, 26Oct 1, 2026 | Bernstein Harold Direct | Sell | $434.7K$434,743.31 |
| Oct 1, 26Oct 1, 2026 | Coloma Jason V Indirect | Sell | $862.2K$862,186.07 |
| Oct 1, 26Oct 1, 2026 | Coloma Jason V Indirect | Sell | $70.1K$70,073.49 |
| Sep 29, 26Sep 29, 2026 | Dandekar Atul Direct | Sell | $202.9K$202,920.75 |
| Sep 4, 26Sep 4, 2026 | Bernstein Harold Direct | Sell | $254.5K$254,501.98 |
1–10 of 92
Summary
Insiders reported 0 buys worth $0.00 and 92 sells worth $19.58M over the last 12 months. That adds up to net selling of $19.58M. Coloma Jason V was the most active insider with 29 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Maze Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about MAZE's management, answered from reported figures.
Who manages MAZE?
Maze Therapeutics, Inc. (MAZE) lists 12 active executives. The top listed executive is Misbah Tahir, CFO & Principal Accounting Officer.
Are MAZE insiders buying or selling?
Recent insider activity shows net buying of $1.57M.
Continue the stock analysis
Jump to another research area for this company.